Abbvie Inc Stock Fair Value – 2023: AbbVie Clinical Updates Demonstrate Successful Results for Inflammatory Drug Treatments Skyrizi and Rinvoq.
March 26, 2023
Trending News ☀️
ABBVIE ($NYSE:ABBV): In the year 2023, AbbVie has announced clinical updates on their inflammatory drugs, Skyrizi and Rinvoq. The study for Skyrizi was conducted for ulcerative colitis and has successfully met its primary endpoint. Meanwhile, the study for Rinvoq was done for systemic lupus erythematosus and has also met its primary endpoint. The success of these clinical updates showcases AbbVie’s commitment to creating effective drugs that can address the needs of those suffering from inflammatory diseases.
The results of these studies represent the hard work and dedication that AbbVie has put forth in its research and development efforts. With these successful results, AbbVie looks forward to continuing its work in providing relief to those affected by these diseases with its own innovative solutions.
Stock Price
On Friday, ABBVIE INC stock opened at $155.3 and closed at $158.0, indicating a market-wide approval of their successful results. This is an increase of 1.8% from the previous closing price of $155.3. This represents a positive outlook for the company as it moves forward in its development of treatments for inflammatory conditions. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abbvie Inc. More…
| Total Revenues | Net Income | Net Margin |
| 58.05k | 11.78k | 21.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abbvie Inc. More…
| Operations | Investing | Financing |
| 24.94k | -623 | -24.8k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abbvie Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 138.81k | 121.52k | 9.04 |
Key Ratios Snapshot
Some of the financial key ratios for Abbvie Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.4% | 12.1% | 27.1% |
| FCF Margin | ROE | ROA |
| 41.8% | 59.1% | 7.1% |
Analysis – Abbvie Inc Stock Fair Value
At GoodWhale, we conducted an analysis of the fundamentals of ABBVIE INC. After considering its P/E ratio, EPS growth rate, dividend yield and other factors, we determined its intrinsic value to be around $135.3 using our proprietary Valuation Line. Currently, ABBVIE INC stock is trading at $158.0, a fair price that is overvalued by 16.8%. More…
Peers
AbbVie Inc is a global, research-based biopharmaceutical company formed in 2013. AbbVie combines the focus and passion of a leading-edge biotech with the experience and breadth of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
Kwang Dong Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceuticals Co Ltd, Vivesto AB are all competitors of AbbVie Inc.
– Kwang Dong Pharmaceutical Co Ltd ($KOSE:009290)
Kwang Dong Pharmaceutical Co Ltd is a South Korean company that manufactures and sells pharmaceutical products. The company has a market cap of 233.75 billion as of 2022 and a return on equity of 19.33%. Kwang Dong Pharmaceutical Co Ltd manufactures a wide range of pharmaceutical products, including antibiotics, anti-inflammatory drugs, and cardiovascular drugs. The company also has a research and development department that is responsible for developing new drugs and formulations.
– Jiangsu Hengrui Pharmaceuticals Co Ltd ($SHSE:600276)
Jiangsu Hengrui Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that engages in the research, development, manufacture, and sale of chemical and biological drugs in China and internationally. The company has a market cap of 248.78 billion as of 2022 and a return on equity of 6.72%. Jiangsu Hengrui Pharmaceutical Co., Ltd. is headquartered in Lianyungang, China.
– Vivesto AB ($OTCPK:OASMY)
Vivesto AB is a Swedish company that provides financial technology solutions. The company has a market capitalization of 32.61 million as of 2022 and a return on equity of -9.39%. Vivesto’s products and services include online banking, mobile banking, and payments solutions. The company serves retail, corporate, and institutional clients.
Summary
ABBVIE Inc. is an attractive investment opportunity as the company has demonstrated successful results for its inflammatory drug treatments Skyrizi and Rinvoq in clinical updates. Recent news coverage of the company has been mostly positive, suggesting that investors are seeing potential in ABBVIE’s long-term growth trajectory. Overall, ABBVIE is in a strong position to continue to deliver strong returns for investors in the future.
